- Home
- PHR
PHR
Phreesia Inc.
as 03-25-2025 9:56am EST
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 1.6B | IPO Year: | 2019 |
| Target Price: | $31.14 | AVG Volume (30 days): | 562.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.07 - $30.53 | Next Earning Date: | 03-12-2025 |
| Revenue: | $419,813,000 | Revenue Growth: | 17.83% |
| Revenue Growth (this year): | 14.67% | Revenue Growth (next year): | 11.87% |
Stock Insider Trading Activity of Phreesia Inc. (PHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Linetsky David | PHR | SVP, Life Sciences | Mar 18 '25 | Sell | $27.70 | 127 | $3,504.94 | 8,731 | |
| Roberts Evan | PHR | Chief Operating Officer | Feb 18 '25 | Sell | $30.03 | 3,696 | $111,073.90 | 741,020 | |
| Hoffman Allison C | PHR | General Counsel & Secretary | Feb 18 '25 | Sell | $29.72 | 3,496 | $103,901.12 | 142,630 | |
| Gandhi Balaji | PHR | Chief Financial Officer | Feb 18 '25 | Sell | $30.02 | 5,867 | $176,257.00 | 105,514 | |
| Roberts Evan | PHR | Chief Operating Officer | Feb 13 '25 | Sell | $30.06 | 19,591 | $588,190.61 | 741,020 | |
| Linetsky David | PHR | SVP, Life Sciences | Feb 13 '25 | Sell | $29.70 | 11,616 | $345,001.01 | 8,731 | |
| Gandhi Balaji | PHR | Chief Financial Officer | Feb 13 '25 | Sell | $30.04 | 33,648 | $1,009,858.50 | 105,514 | |
| Linetsky David | PHR | SVP, Life Sciences | Feb 7 '25 | Sell | $29.52 | 300 | $8,856.99 | 8,731 | |
| Linetsky David | PHR | SVP, Life Sciences | Feb 5 '25 | Sell | $29.50 | 720 | $21,240.94 | 8,731 | |
| Linetsky David | PHR | SVP, Life Sciences | Jan 29 '25 | Sell | $29.68 | 500 | $14,841.00 | 8,731 |
Latest Phreesia Inc. News
PHR Breaking Stock News: Dive into PHR Ticker-Specific Updates for Smart Investing
StockStory
6 days ago
1 Small-Cap Stock with Solid Fundamentals and 2 to Ignore
Zacks
11 days ago
Company News for Mar 14, 2025
Simply Wall St.
11 days ago
Exploring Three High Growth Tech Stocks In The US Market
StockStory
11 days ago
Q4 Earnings Review: Healthcare Technology for Providers Stocks Led by Phreesia (NYSE:PHR)
Business Wire
12 days ago
Phreesia Named to G2’s List of 2025 Best Healthcare Software Products
Thomson Reuters StreetEvents
12 days ago
Q4 2025 Phreesia Inc Earnings Call
Simply Wall St.
12 days ago
Is Phreesia, Inc. (NYSE:PHR) Expensive For A Reason? A Look At Its Intrinsic Value
GuruFocus.com
13 days ago
Phreesia Inc (PHR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow
Compare PHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHR Phreesia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.